Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain

被引：1

作者：

Iriuchishima, Hirono ^{[1
]}

Saito, Akio ^{[1
]}

Mihara, Masahiro ^{[1
]}

Terasaki, Yukie ^{[1
]}

Matsumoto, Akira ^{[1
]}

Isoda, Atsushi ^{[1
,2
]}

Furukawa, Yusuke ^{[3
]}

Matsumoto, Morio ^{[1
]}

机构：

[1] Shibukawa Med Ctr, Dept Hematol, 383 Shiroi, Shibukawa, Gunma, Japan

[2] Hoshi Clin, Dept Hematol, Maebashi, Gunma, Japan

[3] Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, Shimotsuke, Tochigi, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2024年 / 120卷 / 01期

关键词：

Daratumumab; 1q21; gain; Newly-diagnosed multiple myeloma; OPEN-LABEL; PLUS LENALIDOMIDE; DEXAMETHASONE; BORTEZOMIB; PREDNISONE; MELPHALAN; PROGNOSIS; FISH;

D O I：

10.1007/s12185-024-03760-w

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Gain and amplification of 1q21 (1q21+) are adverse chromosomal aberrations of multiple myeloma (MM) that lead to refractoriness to a variety of therapies. While it is known that daratumumab, an anti-cancer monoclonal antibody, cannot overcome the disadvantage of 1q21+in relapsed/refractory MM patients, its benefit in newly diagnosed MM (NDMM) patients with 1q21+has not been clarified. Patients We retrospectively evaluated 11 (55%) 1q21+patients (3 copies: 6, > 4 copies: 5) among 20 NDMM patients (median age, 74 years) who received daratumumab-containing regimens at Shibukawa Medical Center from October 2019 to October 2022. Results The overall response rate was 82% for patients with 1q21+and 78% for patients without 1q21+. Median progression-free survival (PFS) and median overall survival (OS) were not reached in either group. Neither 1q21 copy number nor co-existence of other high-risk cytogenetic abnormalities significantly affected PFS or OS. Conclusion Our preliminary data suggests that outcomes of daratumumab treatment in NDMM 1q21+patients might be non-inferior to those in non-1q21+patients.

引用

页码：71 / 79

页数：9

共 30 条

[1] Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities [J].

Abdallah, Nadine ;

Greipp, Patricia ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Ketterling, Rhett ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. .

BLOOD ADVANCES, 2020, 4 (15) :3509-3519

[2]

ash.confex, PAPER NEW RISK STRAT

[3] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study [J].

Bahlis, Nizar J. ;

Dimopoulos, Meletios A. ;

White, Darrell J. ;

Benboubker, Lotfi ;

Cook, Gordon ;

Leiba, Merav ;

Ho, P. Joy ;

Kim, Kihyun ;

Takezako, Naoki ;

Moreau, Philippe ;

Kaufman, Jonathan L. ;

Krevvata, Maria ;

Chiu, Christopher ;

Qin, Xiang ;

Okonkwo, Linda ;

Trivedi, Sonali ;

Ukropec, Jon ;

Qi, Ming ;

San-Miguel, Jesus .

LEUKEMIA, 2020, 34 (07) :1875-1884

[4] Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance [J].

Baysal, Mehmet ;

Demirci, Ufuk ;

Umit, Elif ;

Kirkizlar, Hakki Onur ;

Atli, Emine Ikbal ;

Gurkan, Hakan ;

Gulsaran, Sedanur Karaman ;

Bas, Volkan ;

Mail, Cisem ;

Demir, Ahmet Muzaffer .

SCIENTIFIC REPORTS, 2020, 10 (01)

[5] Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project [J].

D'Agostino, Mattia ;

Cairns, David A. ;

Lahuerta, Juan Jose ;

Wester, Ruth ;

Bertsch, Uta ;

Waage, Anders ;

Zamagni, Elena ;

Mateos, Maria-Victoria ;

Dall'Olio, Daniele ;

van de Donk, Niels W. C. J. ;

Jackson, Graham ;

Rocchi, Serena ;

Salwender, Hans ;

Creixenti, Joan Blade ;

van der Holt, Bronno ;

Castellani, Gastone ;

Bonello, Francesca ;

Capra, Andrea ;

Mai, Elias K. ;

Durig, Jan ;

Gay, Francesca ;

Zweegman, Sonja ;

Cavo, Michele ;

Kaiser, Martin F. ;

Goldschmidt, Hartmut ;

Hernandez Rivas, Jesus Maria ;

Larocca, Alessandra ;

Cook, Gordon ;

San-Miguel, Jesus F. ;

Boccadoro, Mario ;

Sonneveld, Pieter .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) :3406-+

[6] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J].

de Weers, Michel ;

Tai, Yu-Tzu ;

van der Veer, Michael S. ;

Bakker, Joost M. ;

Vink, Tom ;

Jacobs, Danielle C. H. ;

Oomen, Lukas A. ;

Peipp, Matthias ;

Valerius, Thomas ;

Slootstra, Jerry W. ;

Mutis, Tuna ;

Bleeker, Wim K. ;

Anderson, Kenneth C. ;

Lokhorst, Henk M. ;

van de Winkel, Jan G. J. ;

Parren, Paul W. H. I. .

JOURNAL OF IMMUNOLOGY, 2011, 186 (03) :1840-1848

[7]

Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0

[8]

Dimopoulos MA, 2021, LANCET ONCOL, V22, P801, DOI 10.1016/S1470-2045(21)00128-5

[9] 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib [J].

Du, Chenxing ;

Mao, Xuehan ;

Xu, Yan ;

Yan, Yuting ;

Yuan, Chenglu ;

Du, Xin ;

Liu, Jiahui ;

Fan, Huishou ;

Wang, Qi ;

Sui, Weiwei ;

Deng, Shuhui ;

Fu, Mingwei ;

Li, Zengjun ;

Li, Chengwen ;

Zhao, Jiawei ;

Yi, Shuhua ;

Liu, Lanting ;

Hao, Mu ;

Zou, Dehui ;

Zhao, Yaozhong ;

Qiu, Lugui ;

An, Gang .

LEUKEMIA & LYMPHOMA, 2020, 61 (05) :1201-1210

[10] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma [J].

Facon, T. ;

Kumar, S. ;

Plesner, T. ;

Orlowski, R. Z. ;

Moreau, P. ;

Bahlis, N. ;

Basu, S. ;

Nahi, H. ;

Hulin, C. ;

Quach, H. ;

Goldschmidt, H. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Mace, J. R. ;

Raje, N. ;

Attal, M. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Ahmadi, T. ;

Chiu, C. ;

Wang, J. ;

Van Rampelbergh, R. ;

Uhlar, C. M. ;

Kobos, R. ;

Qi, M. ;

Usmani, S. Z. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) :2104-2115

← 1 2 3 →